PriceTargets.com logo

Fulgent Genetics - FLGT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.00
  • Forecasted Upside: 24.28%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$36.21 As of 02/3/2023 01:00 AM ET
▼ -0.06 (-0.17%)

This chart shows the closing price for FLGT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fulgent Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FLGT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FLGT

Analyst Price Target is $45.00
▲ +24.28% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Fulgent Genetics in the last 3 months. The average price target is $45.00, with a high forecast of $50.00 and a low forecast of $40.00. The average price target represents a 24.28% upside from the last price of $36.21.

This chart shows the closing price for FLGT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Fulgent Genetics. This rating has held steady since September 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/5/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2022Piper SandlerDowngradeOverweight ➝ Neutral$65.00 ➝ $40.00Low
11/18/2022Raymond JamesInitiated CoverageOutperform$45.00Low
11/14/2022Credit Suisse GroupLower TargetOutperform$65.00 ➝ $50.00Low
11/14/2022Piper SandlerLower TargetOverweight$70.00 ➝ $65.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$65.00Low
5/15/2022Piper SandlerLower Target$85.00 ➝ $70.00Medium
3/1/2022Piper SandlerBoost Target$80.00 ➝ $85.00High
1/25/2022OppenheimerLower TargetOutperform$141.00 ➝ $125.00High
8/10/2021Credit Suisse GroupBoost TargetUnderperform$55.00 ➝ $65.00High
3/5/2021Piper SandlerBoost TargetOverweight$135.00 ➝ $140.00High
2/3/2021Piper SandlerBoost TargetOverweight$100.00 ➝ $135.00High
2/1/2021OppenheimerBoost TargetOutperform$75.00 ➝ $130.00Low
1/8/2021Credit Suisse GroupDowngradeNeutral ➝ Underperform$42.00 ➝ $40.00High
11/24/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
11/10/2020Piper SandlerBoost TargetOverweight$73.00 ➝ $100.00Medium
11/1/2020OppenheimerReiterated RatingBuy$75.00High
9/25/2020CSFBBoost TargetNeutral$13.00 ➝ $42.00Low
9/25/2020Credit Suisse GroupBoost TargetNeutral$13.00 ➝ $42.00Medium
8/27/2020OppenheimerReiterated RatingBuy$75.00High
8/19/2020OppenheimerInitiated CoverageOutperform$75.00High
8/17/2020Piper SandlerBoost TargetOverweight$68.00 ➝ $73.00High
8/5/2020Piper SandlerBoost TargetOverweight$31.00 ➝ $68.00High
7/27/2020Piper SandlerBoost TargetOverweight$21.00 ➝ $31.00High
6/17/2020Piper SandlerBoost TargetOverweight$18.00 ➝ $21.00High
5/29/2020BTIG ResearchInitiated CoverageBuy$20.00High
5/5/2020CSFBLower TargetNeutral$12.00 ➝ $11.00High
5/5/2020Credit Suisse GroupLower TargetNeutral$12.00 ➝ $11.00High
5/5/2020Piper SandlerBoost TargetOverweight$16.50 ➝ $18.00High
3/11/2020Piper SandlerBoost TargetHigh
3/11/2020Credit Suisse GroupReiterated RatingHoldHigh
11/5/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$9.50 ➝ $12.30High
8/6/2019Piper Jaffray CompaniesBoost TargetNeutral$5.30 ➝ $9.50High
4/26/2019Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
8/7/2018Piper Jaffray CompaniesReiterated RatingHold$5.10Medium
5/9/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$6.00 ➝ $5.00Low
3/1/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$6.50 ➝ $6.00High
3/1/2018Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
(Data available from 2/5/2018 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/8/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 3 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2023

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fulgent Genetics logo
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
Read More

Today's Range

Now: $36.21
Low: $35.65
High: $37.43

50 Day Range

MA: $32.72
Low: $29.23
High: $37.07

52 Week Range

Now: $36.21
Low: $28.53
High: $73.47

Volume

366,350 shs

Average Volume

194,178 shs

Market Capitalization

$1.07 billion

P/E Ratio

4.16

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Fulgent Genetics?

The following Wall Street analysts have issued research reports on Fulgent Genetics in the last year: Credit Suisse Group AG, Piper Sandler, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for FLGT.

What is the current price target for Fulgent Genetics?

3 Wall Street analysts have set twelve-month price targets for Fulgent Genetics in the last year. Their average twelve-month price target is $45.00, suggesting a possible upside of 24.3%. Credit Suisse Group AG has the highest price target set, predicting FLGT will reach $50.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $40.00 for Fulgent Genetics in the next year.
View the latest price targets for FLGT.

What is the current consensus analyst rating for Fulgent Genetics?

Fulgent Genetics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FLGT will outperform the market and that investors should add to their positions of Fulgent Genetics.
View the latest ratings for FLGT.

What other companies compete with Fulgent Genetics?

Other companies that are similar to Fulgent Genetics include Viridian Therapeutics, CareDx, RadNet, Progenity and Castle Biosciences. Learn More about companies similar to Fulgent Genetics.

How do I contact Fulgent Genetics' investor relations team?

Fulgent Genetics' physical mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company's listed phone number is (626) 350-0537 and its investor relations email address is [email protected] The official website for Fulgent Genetics is www.fulgentgenetics.com. Learn More about contacing Fulgent Genetics investor relations.